Immunology

Lymphocyte Activation Gene-3 Molecule a Useful Vaccine Adjuvant in Mice

Published in Vaccine Weekly, July 26th, 2000

Using both a particulate antigen (hepatitis B surface Ag) and a soluble antigen (OVA) to vaccinate mice, researchers in France have determined that lymphocyte activation gene-3 (LAG-3) can be used to enhance the effectiveness of certain subunit vaccines.

In discussing the theory behind their in vivo study, S. Elmir and co-investigators at the Institute Gustave Roussy in Villejuif, France, said, "The lymphocyte activation gene-3 (LAG-3) product is a MHC (major histocompatibility complex) class II ligand that has been used in vivo to stimulate MHC II+ APCs (antigen-presenting cells) to increase tumor-specific immune responses."

To look at the effect of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2000-07-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry